DB06364ExperimentalSmall molecule
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
- Mechanism
- Curator reviewed
XR5944 is a novel DNA targeting agent that in preclinical studies has demonstrated a high level of anti-tumor activity, both in vitro and in vivo, against a number of human tumor models. In human tumor xenograft models, treatment with XR5944 caused both partial and complete regression of large established tumors.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Formula / weight
- C34H34N8O2 · 586.7 g/mol (avg)
- Code names
- MLN944 · XR-5944
Resolves to
Structure
InChIKey
SFOADSRLCHRTKT-UHFFFAOYSA-NSMILES[H]N(CCN([H])CCN([H])C(=O)C1=CC=CC2=NC3=CC=CC(C)=C3N=C12)CCN([H])C(=O)C1=CC=CC2=NC3=CC=CC(C)=C3N=C12Targets
What you can answer from here — as of March 06, 2025
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with XR5944, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account